Cristina Meazza1, Chiara Gertosio2, Sara Pagani1, Alba Pilotta3, Carmine Tinelli4, Fabio Buzi5, Giovanni Farello6, Giulia Genoni7, Gianni Bona7, Mauro Bozzola8. 1. Pediatrics and Adolescentology Unit, Internal Medicine and Therapeutics Department, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 2. University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. 3. Department of Pediatrics, Auxoendocrinology Centre, University of Brescia, Spedali Civili, Brescia, Italy. 4. Clinical Epidemiology and Biometric Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. 5. Department of Pediatrics, "Carlo Poma" Hospital, Mantova, Italy. 6. Pediatric Unit, Department of Life Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. 7. Division of Pediatrics, Department of Health Sciences, University of "Piemonte Orientale Amedeo Avogadro", Novara, Italy. 8. Pediatrics and Adolescentology Unit, Internal Medicine and Therapeutics Department, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy - mauro.bozzola@unipv.it.
Abstract
BACKGROUND: Patients with childhood-onset GH deficiency (GHD) are usually retested after achievement of near final height, to verify whether they need to continue GH treatment. We investigated if GH stimulation test is necessary to confirm a persistent status of GHD or if other parameters could be a reliable predictor of GHD persistence. METHODS: One-hundred and sixty-four children with idiopathic GHD (55 females and 109 males) were retested when they reached near final height using GH releasing hormone (GHRH)+arginine test or arginine alone. RESULTS: At diagnosis, 23.8% of patients showed severe GHD (GH peak at diagnosis <5 ng/mL) and 76.2% showed partial GHD (GH peak <10 ng/mL). At time of retesting, 82.1% of severe GHD and 82.4% of partial GHD patients showed transient GHD. IGF-I levels were not different between persistent (0.18±1.18 SDS) and transient GHD subjects (0.17±0.82 SDS). Furthermore, among persistent severe GHD patients only two showed very reduced levels of IGF-I (<-2.0 SDS). CONCLUSIONS: The majority of patients idiopathic GHD proved to be transient. IGF-I levels alone do not discriminate subjects with persistent from those with transient GHD. Therefore, after the end of GH substitutive treatment, a re-evaluation of GH secretion is mandatory to verify the persistence of GHD in adulthood.
BACKGROUND:Patients with childhood-onset GH deficiency (GHD) are usually retested after achievement of near final height, to verify whether they need to continue GH treatment. We investigated if GH stimulation test is necessary to confirm a persistent status of GHD or if other parameters could be a reliable predictor of GHD persistence. METHODS: One-hundred and sixty-four children with idiopathic GHD (55 females and 109 males) were retested when they reached near final height using GH releasing hormone (GHRH)+arginine test or arginine alone. RESULTS: At diagnosis, 23.8% of patients showed severe GHD (GH peak at diagnosis <5 ng/mL) and 76.2% showed partial GHD (GH peak <10 ng/mL). At time of retesting, 82.1% of severe GHD and 82.4% of partial GHD patients showed transient GHD. IGF-I levels were not different between persistent (0.18±1.18 SDS) and transient GHD subjects (0.17±0.82 SDS). Furthermore, among persistent severe GHD patients only two showed very reduced levels of IGF-I (<-2.0 SDS). CONCLUSIONS: The majority of patientsidiopathic GHD proved to be transient. IGF-I levels alone do not discriminate subjects with persistent from those with transient GHD. Therefore, after the end of GH substitutive treatment, a re-evaluation of GH secretion is mandatory to verify the persistence of GHD in adulthood.
Authors: Stephany H Donze; Layla Damen; Janiëlle A E M van Alfen-van der Velden; Gianni Bocca; Martijn J J Finken; Gera J G Hoorweg-Nijman; Petr E Jira; Mariëtte van Leeuwen; Anita C S Hokken-Koelega Journal: Clin Endocrinol (Oxf) Date: 2019-04-30 Impact factor: 3.478
Authors: V Guarnotta; G Pizzolanti; R Petrancosta; S Radellini; C Baiamonte; C Giordano Journal: J Endocrinol Invest Date: 2022-03-13 Impact factor: 5.467